Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]
In development
Reference number: GID-TA11058
Expected publication date: TBC
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Fezolinetant for untreated vasomotor symptoms associated with the menopause.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early December 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.